Insilico Medicine signed a multiyear R&D collaboration with Servier valued at up to $888 million to discover and develop oncology therapeutics using Insilico’s AI discovery platform. The agreement includes near-term R&D payments and shared development responsibilities with Servier leading clinical validation and commercialization. Servier described the partnership as leveraging Insilico’s Pharma.AI capabilities to identify candidates for challenging oncology targets. Servier’s engagement follows Insilico’s recent Hong Kong IPO and signals sustained pharma appetite for AI-driven discovery partners. The deal adds to a wave of large-value AI partnerships and will be watched for concrete drug candidates entering IND-enabling work, as commercial valuations for AI-platform firms hinge on tangible translational milestones.